The market for Cancer Biopsy was valued at US$ 25.75 billion in 2021, and it is anticipated to increase to US$ 66.5 billion by 2027, with a CAGR of 17.9% during 2022 and 2027.
A biopsy is the process of removing tissue in order to examine it for disease. Tissue samples can be taken from any part of the body. Numerous techniques can be used to do biopsies. Some biopsies involve physically removing a suspicious mass or nodule, while others involve collecting a small sample of tissue with a needle. Imaging tests like MRIs and CT scans can help find lumps or abnormal tissue, but they are unable to tell malignant cells from non-cancerous ones. Taking a biopsy and collecting cells for additional examination is the sole way to diagnose the majority of cancers.
The rise of the cancer biopsy market is projected to be fueled by the ageing global population and the increased incidence of cancer symptoms. The development of liquid biopsy techniques is also anticipated to advance the cancer biopsy industry. Many techniques, including skin, needle, bone marrow, endoscopic, and surgical biopsies, are widely utilized in the field of oncology diagnostics. Among these methods, needle biopsies are recognized as a preferred tool for patient early detection. However, advantages of fine needle aspiration needle biopsies, including decreased invasion and quicker results, have led to an expansion of the cancer biopsy industry. Globally, there are now a much greater number of people who have cancer. Some of the factors contributing to the rise in cancer cases include environmental factors, cigarette smoking, infectious disorders including Hepatitis B and C, as well as lifestyle changes. Liquid biopsy has several benefits over conventional cancer diagnostic techniques, including lower cost, early prognosis, therapy monitoring, tumor heterogeneity discovery, acquired drug resistance, and patient comfort (by eliminating the need for surgery). In conjunction with the rise in cancer prevalence, it is therefore projected that preference for liquid biopsies will rise during the projection period.
March 28, 2019: QIAGEN launches novel liquid biopsy solutions and NGS panels with seamlessly integrated bioinformatics to support advances in cancer research --
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of new solutions designed to advance cancer research as part of its highlights at the American Association for Cancer Research (AACR) 2019 Annual Meeting from March 29 to April 3, 2019, in Atlanta, Georgia. More than 30 studies being presented at AACR 2019 cite molecular testing tools from QIAGEN’s Sample to Insight portfolio.
Market is segmented based on the type, applications, companies and regions.
By Type, it is segmented into
By Application, it is segmented into
In 2020, North America had the largest share (more than 40.0%). With the U.S. significantly contributing to regional revenue, the region is expected to maintain its lead during the projected period. Additionally, companies working in this region that distribute and create new kits with applications for rapid diagnostics are their main goals.
Furthermore, the lucrative techniques outlined by the relevant government authorities have been a major factor in the growing use of liquid biopsies across the United States. The framework, which the US Food and Drug Administration created in recent years, serves as the foundation for regulatory policies for liquid biopsy-based oncology diagnostics (FDA). The rules governing enrichment biomarkers, companion diagnostics, and approval precedents make up this framework. The FDA's approval of tests established under the Clinical Laboratory Improvement Amendment (CLIA) has added value to the regulatory paths for liquid biopsy.
The Cancer Biopsy Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Cancer Biopsy Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
Report Attributes | Report Details |
Forecast Period 2022 to 2027 CAGR | CAGR of 17.9% over the forecast period (2022-2027) |
By Type |
|
By Application |
|
By Companies | Qiagen N.V., Illumina, Inc., ANGLE Plc, Myriad Genetics, Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher, Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health, Exact Sciences Corporation, Freenome Holdings, Inc., Oncimmune, Chronix Biomedical, Inc., Personal Genome Diagnostics Inc., Bio-Rad Laboratories Inc., Agena Bioscience Inc., Exosome Diagnostics Inc., F. Hoffmann-La Roche Ltd |
Regions Covered |
|
Countries Covered |
|
Base Year | 2022 |
Historical Year | 2017 to 2021 |
Forecast Year | 2022 to 2027 |
Number of Pages | 86 |
Customization Available | Yes, the report can be customized as per your needs |
What is the growth rate of Cancer Biopsy Market?
The Cancer Biopsy Market is growing at a CAGR of 17.9% over the next 5 years.
Who are the key players in Cancer Biopsy Market?
Qiagen N.V., Illumina, Inc., ANGLE Plc, Myriad Genetics, Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher, Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health, Exact Sciences Corporation, Freenome Holdings, Inc., Oncimmune, Chronix Biomedical, Inc., Personal Genome Diagnostics Inc., Bio-Rad Laboratories Inc., Agena Bioscience Inc., Exosome Diagnostics Inc., F. Hoffmann-La Roche Ltd
What are the significant types of Cancer Biopsy Market?
Tissue Biopsies, Liquid Biopsies, Others
What are the major end-use applications of Cancer Biopsy Market?
Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Others
All our reports are custom made to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report as your needs.
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
Reach us with your research requirements and we shall provide the optimum solution to suit your needs.
Discounts available for multiple report purchases.